Table 2.
Medication after HTX
| Parameter | All (n = 639) | No cRBBB ≤ 30 days after HTX (n = 500) | cRBBB ≤ 30 days after HTX (n = 139) | Difference | 95% CI | P‐value |
|---|---|---|---|---|---|---|
| Immunosuppressive drug therapy | ||||||
| Cyclosporine A, n (%) | 347 (54.3%) | 273 (54.6%) | 74 (53.2%) | 1.4% | −8.0%–10.8% | 0.78 |
| Tacrolimus, n (%) | 292 (45.7%) | 227 (45.4%) | 65 (46.8%) | 1.4% | −8.0%–10.8% | 0.78 |
| Azathioprine, n (%) | 267 (41.8%) | 208 (41.6%) | 59 (42.4%) | 0.8% | −8.5%–10.1% | 0.86 |
| Mycophenolate mofetil, n (%) | 372 (58.2%) | 292 (58.4%) | 80 (57.6%) | 0.8% | −8.5%–10.1% | 0.86 |
| Steroids, n (%) | 639 (100.0%) | 500 (100.0%) | 139 (100.0%) | 0.0% | n.a. | n.a. |
| Concomitant medication | ||||||
| ASA, n (%) | 68 (10.6%) | 50 (10.0%) | 18 (12.9%) | 2.9% | −3.3%–9.1% | 0.32 |
| Beta blocker, n (%) | 114 (17.8%) | 93 (18.6%) | 21 (15.1%) | 3.5% | −3.4%–10.4% | 0.34 |
| Ivabradine, n (%) | 61 (9.5%) | 50 (10.0%) | 11 (7.9%) | 2.1% | −3.1%–7.3% | 0.46 |
| Calcium channel blocker, n (%) | 171 (26.8%) | 130 (26.0%) | 41 (29.5%) | 3.5% | −5.0%–12.0% | 0.41 |
| ACE inhibitor/ARB, n (%) | 278 (43.5%) | 229 (45.8%) | 49 (35.3%) | 10.5% | 1.5%–19.5% | 0.03* |
| Diuretic, n (%) | 639 (100.0%) | 500 (100.0%) | 139 (100.0%) | 0.0% | n.a. | n.a. |
| Statin, n (%) | 254 (39.7%) | 200 (40.0%) | 54 (38.8%) | 1.2% | −8.0%–10.4% | 0.81 |
| Gastric protection a , n (%) | 639 (100.0%) | 500 (100.0%) | 139 (100.0%) | 0.0% | n.a. | n.a. |
ACE inhibitor, angiotensin‐converting‐enzyme inhibitor; ARB, angiotensin II receptor blocker; ASA, acetylsalicylic acid; CI, confidence interval; cRBBB, complete right bundle branch block; HTX, heart transplantation; n, number; n.a., not applicable.
a
Gastric protection defined as proton pump inhibitor (PPI) or histamine receptor (H2) blocker.
*
Statistically significant at P < 0.05.